Study on coagulation function and survival status of patients with long-term aspirin cerebral hemorrhage

doi:10.3877/cma.j.issn.2095-123X.2019.02.010

Abstract

Abstract:

Objective

To investigate the effects of long-term use of aspirin on coagulation function and survival and prognosis in patients with cerebral hemorrhage.

Methods

A retrospective analysis of 95 patients with cerebral hemorrhage who were treated in our hospital from September 2010 to September 2017 was performed. The long-term use of aspirin during the study period was divided into experimental group and control group. The experimental group took long-term use of aspirin before onset, the control group did not take aspirin. The patient’s venous blood was taken for blood test within 8 h after the onset of the disease, and the patient’s blood coagulation function index was explored. The United States National Institute of Health stroke scale was used to evaluate the neurological function of patients before and after treatment, and the continuous bleeding, enlarged hematoma volume and mortality were compared between the two groups.

Results

The platelet count in the experimental group was significantly lower than that in the control group, and the thrombin time and activated thrombin time in the experimental group were significantly higher than those in the control group (P<0.05). The incidence of hemorrhage, enlarged hematoma area, mortality and NIHSS score in the experimental group were significantly higher than those in the control group (P<0.05).

Conclusion

Long-term use of aspirin may affect the patient’s coagulation function, which severely increase the mortality of patients.

Key words: Cerebral hemorrhage, Coagulation function, Survival status

Chunhu Li, Hongbo Jin, Quanle Zheng, Jiarui Zhang, Shunyi Zhou, Tongle Zhang. Study on coagulation function and survival status of patients with long-term aspirin cerebral hemorrhage[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2019, 09(02): 106-108.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2019.02.010

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2019/V09/I02/106

Figures/Tables 1

References 15

[11]	梁茜茜，张庆，李莉等.阿司匹林联合氯吡格雷治疗急性脑梗死的临床研究[J].中国临床药理学杂志, 2016, 32(16): 1446-1448.
[12]	武钟毅，王保爱.阿司匹林联合氯吡格雷治疗进展性脑梗死的有效性与安全性[J].中西医结合心脑血管病杂志, 2015, 13(3): 366-368.
[13]	孟明，张春梅，赵旭伟,等.阿司匹林联合阿托伐他汀对脑卒中大鼠脑组织神经生长相关蛋白43与血管内皮生长因子表达的影响及治疗老年急性缺血性脑卒中的疗效[J].中国老年学杂志, 2015, 35(10): 2641-2644.
[1]	Wang K, Li H, Liu W, et al. Seasonal variation in spontaneous intracerebral hemorrhage frequency in Chengdu, China, is independent of conventional risk factors[J]. J Clin Neurosci, 2013, 20(4): 565-569.
[2]	Ishihara H, Kunitsugu I, Nomura S, et al. Seasonal variation in the incidence of aneurysmal subarachnoid hemorrhage associated with age and gender: 20-year results from the Yamaguchi cerebral aneurysm registry[J]. Neuroepidemiology, 2013, 41(1): 7-12.
[3]	Schols AM, Schreuder FH, van Raak EP, et al. Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands[J]. Stroke, 2014, 45(1): 268-270.
[4]	杨成，钱捷，唐迅,等.阿司匹林单独或与氯吡格雷联合用药治疗缺血性脑卒中及短暂性脑缺血发作疗效和不良反应的Meta分析[J].中华流行病学杂志, 2015, 36(12): 1430-1435.
[5]	赵亚男，王晨，蔚有权,等.氯吡格雷联合阿司匹林治疗急性心肌梗死的临床研究[J].中国临床药理学杂志, 2015, 31(8): 595-598.
[6]	朱明慧，王辉，徐艳,等.脑出血、脑梗死急性发作期患者血压、血脂、凝血纤溶功能差异及意义[J].山东医药, 2017, 57(4): 66-68.
[7]	史立信，臧颖卓，王清涛,等.阿司匹林相关性脑出血患者的预后、部分凝血指标改变与对策[J].脑与神经疾病杂志, 2016, 24(4): 236-240.
[8]	李萍，赵树明，胡亚男,等.脑出血发病机制研究进展[J].中华老年心脑血管病杂志, 2015, 17(2): 214-215.
[9]	童艳飞，张佩兰. NIHSS评分≥15分且发病时间≤4.5h的重型脑梗死患者静脉溶栓的疗效观察[J].实用医学杂志, 2016, 32(5): 812-815.
[10]	陈锦雄，陈炳星，陈囯新,等.阿托伐他汀联合阿司匹林治疗高血压伴发动脉粥样硬化的临床研究[J].中国临床药理学杂志, 2015, 31(13): 1236-1238.
[14]	李朝晖，黄哲浩，李庆伟.应用抗栓药物的颅内出血患者凝血功能障碍的纠正策略研究进展[J].国际神经病学神经外科学杂志, 2016, 43(5): 477-481.
[15]	巩法桃，焉传祝.高血压脑出血患者血肿扩大的影响因素[J].中华老年心脑血管病杂志, 2016, 18(4): 447-448.

组别	例数	凝血功能（Mean±SD）			生存状况			NIHSS评分（Mean±SD，分)
组别	例数	PLT（×10⁹L）	TT（s）	APTT（s）	术后出血[例（%）]	血肿增大体积（Mean±SD, cm²）	死亡[例（%）]	NIHSS评分（Mean±SD，分)
试验组	49	96.43±8.31	21.27±2.31	37.56±8.22	12（24.49）	52.31±2.31	15（30.61）	20.27±5.81
对照组	46	110.29±10.28	18.44±2.21	31.89±9.42	4（8.70）	43.39±3.20	4（8.70）	16.78±3.62
t/χ²值	?	-7.247	6.094	3.131	4.226	15.540	7.123	3.487
P值	?	0.001	0.001	0.002	0.040	0.001	0.008	0.001

组别	例数	凝血功能（Mean±SD）			生存状况			NIHSS评分（Mean±SD，分)
组别	例数	PLT（×10⁹L）	TT（s）	APTT（s）	术后出血[例（%）]	血肿增大体积（Mean±SD, cm²）	死亡[例（%）]	NIHSS评分（Mean±SD，分)
试验组	49	96.43±8.31	21.27±2.31	37.56±8.22	12（24.49）	52.31±2.31	15（30.61）	20.27±5.81
对照组	46	110.29±10.28	18.44±2.21	31.89±9.42	4（8.70）	43.39±3.20	4（8.70）	16.78±3.62
t/χ²值	?	-7.247	6.094	3.131	4.226	15.540	7.123	3.487
P值	?	0.001	0.001	0.002	0.040	0.001	0.008	0.001

Please choose a citation manager

Content to export